Pier 88 Investment Partners LLC Sells 95,810 Shares of Health Catalyst, Inc. $HCAT

Pier 88 Investment Partners LLC trimmed its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 41.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 134,060 shares of the company’s stock after selling 95,810 shares during the period. Pier 88 Investment Partners LLC owned about 0.19% of Health Catalyst worth $505,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock valued at $163,000 after purchasing an additional 2,624 shares in the last quarter. Campbell & CO Investment Adviser LLC increased its stake in Health Catalyst by 9.7% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company’s stock worth $162,000 after purchasing an additional 3,808 shares in the last quarter. Probity Advisors Inc. raised its holdings in Health Catalyst by 18.3% during the 1st quarter. Probity Advisors Inc. now owns 36,313 shares of the company’s stock worth $164,000 after buying an additional 5,621 shares during the period. Focus Partners Wealth bought a new position in Health Catalyst in the first quarter valued at approximately $46,000. Finally, Divergent Planning LLC bought a new position in Health Catalyst in the second quarter valued at approximately $45,000. 85.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. BTIG Research reissued a “neutral” rating on shares of Health Catalyst in a research report on Friday, September 5th. Stifel Nicolaus lowered their target price on Health Catalyst from $5.50 to $4.50 and set a “hold” rating for the company in a report on Friday, August 8th. Canaccord Genuity Group dropped their price target on Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, August 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Health Catalyst in a research report on Tuesday, October 7th. Finally, Wells Fargo & Company dropped their target price on Health Catalyst from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Health Catalyst has an average rating of “Hold” and a consensus target price of $4.55.

Health Catalyst Stock Performance

HCAT opened at $2.83 on Friday. The business’s 50-day simple moving average is $3.05 and its 200 day simple moving average is $3.52. Health Catalyst, Inc. has a 52-week low of $2.52 and a 52-week high of $9.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83. The firm has a market capitalization of $199.15 million, a PE ratio of -1.87 and a beta of 1.64.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.